{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-006779","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2022-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.463844+00:00","generated_at":"2026-06-26T02:10:44.052015+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Janux presents preclinical data for JANX007 and JANX008 at PEGS Boston conference","bullets":["Management presented two posters at PEGS Boston on May 2-5, 2022.","JANX007 is a PSMA-targeted TRACTr for prostate cancer; JANX008 is EGFR-targeted for solid tumors.","Data is preclinical; no clinical results or financial guidance disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-006779","json":"https://secwatch.observer/filing/0000950170-22-006779.json","markdown":"https://secwatch.observer/filing/0000950170-22-006779.md","text":"https://secwatch.observer/filing/0000950170-22-006779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022006779/0000950170-22-006779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022006779/janx-20220502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:10:44.052015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}